Literature DB >> 8064801

Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.

C Sonesson1, C H Lin, L Hansson, N Waters, K Svensson, A Carlsson, M W Smith, H Wikström.   

Abstract

A series of (S)-phenylpiperidines in which the substituents on the aromatic ring and nitrogen have been varied has been prepared. They have been evaluated pharmacologically to explore the importance of these substituents for the interaction with central dopamine (DA) receptors. On the basis of biochemical and behavioral data in rats, several of these compounds are characterized as centrally acting DA autoreceptor antagonists. (S)-Phenylpiperidines having an aromatic substituent with a high group dipole moment in the 3-position, i.e., meta with respect to the piperidine ring, and being N-substituted with a propyl group were found to be highly active in vivo on the synthesis and turnover of dopamine. However, they do not induce strong hypoactivity or catalepsy. Interestingly, the most active compounds in vivo were found to display only low affinity for DA D2 and D3 receptors in vitro. In addition, 7-triflate-substituted octahydrobenzo[f]quinolines and 6-triflate-substituted hexahydro-1H-benz[e]indoles have been prepared and pharmacologically evaluated. The trans isomers of these rigid structures were found to display a pharmacological profile similar to that of the flexible phenylpiperidines. The corresponding cis isomers were found to be inactive in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8064801     DOI: 10.1021/jm00043a013

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

Review 1.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

2.  Stimulating and inhibitory effects of the dopamine "stabilizer" (-)-OSU6162 on dopamine D2 receptor function in vitro.

Authors:  R A Lahti; C A Tamminga; A Carlsson
Journal:  J Neural Transm (Vienna)       Date:  2007-07-06       Impact factor: 3.575

3.  Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization.

Authors:  Johan P Rung; Emilia Rung; Lisa Helgeson; Anette M Johansson; Kjell Svensson; Arvid Carlsson; Maria L Carlsson
Journal:  J Neural Transm (Vienna)       Date:  2008-03-20       Impact factor: 3.575

4.  The substituted (S)-3-phenylpiperidine (-)-OSU6162 reduces apomorphine- and amphetamine-induced behaviour in Cebus apella monkeys.

Authors:  M Brandt-Christensen; M B Andersen; A Fink-Jensen; T Werge; J Gerlach
Journal:  J Neural Transm (Vienna)       Date:  2005-03-30       Impact factor: 3.575

5.  Effects of the dopamine stabilizers (S)-(-)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats.

Authors:  Johan P Rung; Emilia Rung; Anette M Johansson; Kjell Svensson; Arvid Carlsson; Maria L Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-02       Impact factor: 3.000

6.  I. In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors.

Authors:  Maria L Carlsson; Ethan S Burstein; Angélica Kloberg; Sarah Hansson; Arja Schedwin; Marie Nilsson; Johan P Rung; Arvid Carlsson
Journal:  J Neural Transm (Vienna)       Date:  2011-08-28       Impact factor: 3.575

7.  Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor.

Authors:  Elodie Kara; Hong Lin; Kjell Svensson; Anette M Johansson; Philip G Strange
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

8.  The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects.

Authors:  Nelleke Tolboom; Henk W Berendse; Josee E Leysen; Maqsood Yaqub; Bart N M van Berckel; Robert C Schuit; Mirthe M Ponsen; Esther Bakker; Nikie J Hoetjes; Albert D Windhorst; Maria L Carlsson; Adriaan A Lammertsma; Arvid Carlsson
Journal:  Neuropsychopharmacology       Date:  2014-08-05       Impact factor: 7.853

9.  Effects of the monoamine stabilizer (-)-OSU6162 on locomotor and sensorimotor responses predictive of antipsychotic activity.

Authors:  Vívian T da Silveira; Jivago Röpke; Ana L Matosinhos; Ana C Issy; Elaine A Del Bel; Antônio C de Oliveira; Fabrício A Moreira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-04-24       Impact factor: 3.000

10.  Effect of the dopamine stabilizer (-)-OSU6162 on potentiated incubation of opioid craving after electric barrier-induced voluntary abstinence.

Authors:  Ida Fredriksson; Sarah V Applebey; Angelica Minier-Toribio; Aniruddha Shekara; Jennifer M Bossert; Yavin Shaham
Journal:  Neuropsychopharmacology       Date:  2020-01-06       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.